HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF ALK-REARRANGED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED IN SECOND LINE WITH ALECTINIB

被引：0
|
作者：
Greillier, L. [1 ]
Tuzelet, V [2 ]
Cadranel, J. [3 ]
Thiberville, L. [4 ]
Chouaid, C. [5 ]
Girard, N. [6 ]
Cortot, A. B. [7 ]
Felicio, H. [8 ]
Weber, V [8 ]
Pau, D. [8 ]
机构：
[1] APHM, Marseille, France
[2] Keyrus Biopharma, La Chapelle Sur Erdre, France
[3] Hop Tenon, Paris, France
[4] Hop Charles Nicolle, Rouen, France
[5] Creteil Univ Hosp, Dept Chest Med, Creteil, France
[6] Inst Curie, Paris, France
[7] CHRU Lille, Lille, France
[8] Roche, Boulogne, France
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN17
引用
收藏
页码：S423 / S423
页数：1
相关论文
共 50 条
  • [31] Sequential Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study
    Ito, Kentaro
    Hataji, Osamu
    Kobayashi, Hiroyasu
    Fujiwara, Atsushi
    Yoshida, Masamichi
    D'Alessandro-Gabazza, Corina N.
    Itani, Hidetoshi
    Tanigawa, Motoaki
    Ikeda, Takuya
    Fujiwara, Kentaro
    Fujimoto, Hajime
    Kobayashi, Tetsu
    Gabazza, Esteban C.
    Taguchi, Osamu
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) : 390 - 396
  • [32] Health-related quality of life (HRQOL) after stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC).
    Senan, S.
    Gundy, C.
    Haasbeek, C. J.
    Slotman, B. J.
    Aaronson, N. K.
    Lagerwaard, F. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Health-related quality of life (HRQOL) with sunitinib (SU) as maintenance therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Blais, Normand
    Torigoe, Yasuhiro
    Luo Yingchun
    Wei, Greg C.
    Cappelleri, Joseph C.
    Kim, Sindy T.
    Chao, Richard
    Goss, Glenwood
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S667 - S667
  • [34] Concomitant genetic alterations predicted response to alectinib in patients with ALK-rearranged non-small cell lung cancer: A real word study in China
    Chen, X.
    Yu, X.
    Huang, J.
    Lai, J.
    Ding, L.
    Sheng, L.
    Ma, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1052 - S1052
  • [35] Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series
    Myall, Nathaniel J.
    Lei, Amy Q.
    Wakelee, Heather A.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) : 487 - 495
  • [36] Real-World Outcomes of Health-Related Quality-of-Life(HRQoL) In Advanced Non-small Cell Lung Cancer Patients Treated with Aumolertinib
    Li, J.
    Li, H.
    Zhao, W.
    Zhang, Y.
    Wang, J.
    Yi, C.
    Wang, X.
    Liu, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S658 - S659
  • [37] The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
    Pan, Yue
    Deng, Chao
    Qiu, Zhenhua
    Cao, Chenghui
    Wu, Fang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [38] Expanding therapies for crizotinib refractory ALK-rearranged non-small cell lung cancer
    Barnes, Tristan A.
    Leighl, Natasha B.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S458 - S461
  • [39] Ceritinib-a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer
    Rothschild, Sacha I.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 379 - 381
  • [40] Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer
    Santarpia, Mariacarmela
    Altavilla, Giuseppe
    Rosell, Rafael
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (03) : 255 - 268
12345